WHO Raises Alert Over Critical Lack of Obesity Jabs
Under one in 10 individuals eligible to benefit from GLP-1 drugs including Wegovy are able to get them, caution the global health agency as it releases its initial advice on the therapies.
With over a billion individuals worldwide currently obese, it is calling for broader and more equitable availability to GLP-1 medication.
Per forecasts, more than two billion will be living with obesity by 2030 if no action is taken.
"Our new guidance affirms that obesity is a lifelong illness that can be addressed with thorough and lifelong care," stated the agency's head Tedros Adhanom Ghebreyesus.
Significant expense, limited production capacity, and distribution challenges are major barriers to widespread access to the treatments that can help people shift substantial weight, explains the organization.
Skinny Jab Shortage
Even in the present best projected outlook, the manufacturing of these medications might only reach around 100 million people – under 10% of eligible patients, per the health organization.
The recommendation calls on countries and companies to widen access, through measures such as voluntary licensing.
Exclusive production rights on the active ingredient – the primary ingredient of the drug Wegovy – is due to expire in multiple nations in 2026.
The Way Obesity Jabs Work
These medications imitate a natural hormone to delay gastric emptying, suppress the appetite and increase feelings of fullness so users eat less.
Individuals usually begin shedding pounds within a few weeks of starting on the regular doses.
Studies points to people may regain a significant portion within a year of discontinuing the medication, as their normal hunger return.
Being above a healthy weight increases your likelihood for developing medical conditions, like diabetes, heart disease, brain attack, and some malignancies.
Obesity concerns people in countries worldwide and was linked to over three and a half million deaths worldwide in 2024, as per the health agency.
